Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: Effects of MDL 100,907, clozapine, risperidone and haloperidol

Behavioural Brain Research

Volumn 88, Issue 1, 1997, Pages 43-49

  Hitchcock, Janice M ^a   Lister, Sarah ^a   Fischer, Thierry R ^a   Wettstein, Joseph G ^a  

^a SANOFI   (France)

Author keywords

5 HT2; Antipsychotic; Clozapine; DOI; Haloperidol; Latent inhibition; MDL 100,907; Risperidone; Schizophrenia

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2 AGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AUDITORY STIMULATION; CONDITIONING; CONFERENCE PAPER; CONTROLLED STUDY; EXPERIMENTAL MODEL; HABITUATION; LATENT INHIBITION; LICKING; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONDITIONING, OPERANT; FLUOROBENZENES; HALOPERIDOL; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); RISPERIDONE; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STARTLE REACTION;

EID: 0030810083     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)02315-2     Document Type: Conference Paper

References (56)

1. Bakshi, V.P., Swerdlow, N.R. and Geyer, M.A., Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response, J. Pharmacol. Exp. Ther., 271 (1994) 787-794.
2. Baruch, I., Hemsley, D.R. and Gray, J.A., Differential performance of acute and chronic schizophrenics in a latent inhibition task, J. Nerv. Ment. Dis., 176 (1988) 598-606.
3. Braff, D.L. and Geyer, M.A., Sensorimotor gating and schizophrenia: human and animal model studies, Arch. Gen. Psychiat., 47 (1990) 181-188.
4. 1C sites, Eur. J. Pharmacol., 191 (1990) 93-96.
5. Cassaday, H.J., Mitchell, S.N., Williams, J.H. and Gray, J.A., 5,7-Dihydroxytryptamine lesions in the fornix-fimbria attenuate latent inhibition, Behav. Neural Biol., 59 (1993a) 194-207.
6. Cassaday, H.J., Hodges, H. and Gray, J.A., The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat, Psychopharmacology, 7 (1993b) 63-71.
7. Coward, D.M. The pharmacology of clozapine-like, atypical antipsychotics. In: T.R.E. Barnes (Ed.), Antipsychotic Drugs and their Side Effects, Academic Press, San Diego, 1993, pp. 27-45.
8. Dunn, L.A., Atwater, G.E. and Kilts, C.D., Effects of antipsychotic drugs on latent inhibition. Sensitivity and specificity of an animal behavioral model of clinical drug action, Psychopharmacology, 112 (1993) 315-323.
9. Feldon, J. and Weiner, I., The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli, Biol. Psychiat, 29 (1991) 635-646.
10. Feldon, J. and Weiner, I., Abolition of the acquisition but not the expression of latent inhibition by chlordiazepoxide in rats, Pharmacol. Biochem. Behav., 32 (1989) 123-127.
11. 2 receptor involvement in the mechanism of action of hallucinogenic agents, Life Sci., 35 (1984) 2505-2511.
12. Gray, J.A., Feldon, J., Rawlins, J.N.P., Hemsley, D.R. and Smith A.D., The neuropsychology of schizophrenia, Behav. Brain Sci., 14 (1991) 11-84.
13. Gray, J.A., Joseph, M. H., Hemsley, D.R., Young, A.M.J., Warburton, E.C., Boulenguez, P., Grigoryan, G.A., Peters, S.L., Rawlins, J.N.P., Taib, C.-T., Yee, B.K., Cassaday, H., Weiner, I., Gal, G., Gusak, O., Joel, D., Shadach, E., Shalev, U., Tarrasch, R., and Feldon, J. The role of the mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia, Behav. Brain Res., 71 (1995) 19-31.
14. Gray, N.S., Hemsley, D.R. and Gray J.A., Abolition of latent inhibition in acute, but not chronic, schizophrenics, Neurol. Psychiat. Brain Res., 1 (1992a) 83-89.
15. Gray, N.S., Hemsley, D.R. and Gray, J.A., Abolition of latent inhibition by a single 5 mg dose of amphetamine in man, Psychopharmacology, 107 (1992b) 425-430.
16. 2 binding using SPET, Schizophr. Res., 17 (1995) 95-107.
17. 2 antagonistic properties, J. Pharmacol. Exp. Ther., 244 (1988) 685-693.
18. Joseph, M.H., Peters, S.L. and Gray, J.A., Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure, Psychopharmacology, 110 (1993) 187-192.
19. 2A antagonist with a favorable CNS safety profile, J. Pharmacol. Exp. Ther., 277 (1996) 968-981.
20. Killcross, A.S., What is being measured in latent inhibition experiments: dopamine antagonists influence reinforcement and associative interference processes, not attention, Behav. Pharmacol., 5(Suppl. 1) (1994) 49.
21. Killcross, A.S., Dickinson, A. and Robbins, T.W., Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction, Psychopharmacology, 115 (1994) 185-195.
22. Killcross, A.S., Stanhope, K.J., Dourish, C.T. and Piras, G. WAY 100635 and latent inhibition in the rat: selective effects at preexposure, Behav. Brain Res. 88 (1997) 51-57.
23. Killcross, A.S. and Robbins, T.W., Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm, Psychopharmacology, 110 (1993) 479-489.
24. Krauth, J, Distribution Free Statistics: An Application Oriented Approach, Elsevier, Amsterdam, 1988.
25. Leysen, J.E., Gommeren, W., Eens, A., de Courcelles, D.C., Stoof, J.C. and Janssen, P.A.J., Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther., 247 (1988) 661-670.
26. Lubow, R.E, Latent Inhibition and Conditioned Attention Theory, Cambridge University Press, Cambridge, 1989.
27. Lubow, R.E. and Moore, A.U., Latent inhibition: the effect of non-reinforced pre-exposure to the conditioned stimulus, J. Comp. Physiol. Psychol., 52 (1959) 415-419.
28. Lubow, R.E., Weiner, I. and Schnur, P., Conditioned attention theory. In: G.H. Bower (Ed.), The Psychology of Learning and Motivation, Vol. 83, Academic Press, New York, 1981, pp. 1-49.
29. Mackintosh, N.J., Stimulus selection: learning to ignore stimuli that predict no change in reinforcement. In: R.A. Hinde and J.S. Hinde (Eds.), Constraints on Learning: Limitations and Predispositions, Academic Press, Cambridge, 1973, pp. 79-100.
30. 2 receptor in latent inhibition, Behav. Pharmacol., 5 (1994) 120.
31. i values. J. Pharmacol. Exp. Ther., 251 (1989) 238-246.
32. Moran, P.M., Fischer, T.R., Hitchcock, J.M. and Moser P.C. Effects of clozapine on latent inhibition in the rat, Behav. Pharmacol., 7 (1996) 42-48.
33. 2A antagonist, Behav. Brain. Res., 73 (1996) 163-167.
34. Nichols, D.E. and Glennon, R.A., Medicinal chemistry and structure-activity relationships of hallucinogens. In: B.L. Jacobs (Ed.), Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives, Raven Press, New York, 1984, pp. 95-142.
35. Ögren, S.O. and Archer, T., Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile, Psychopharmacology, 114 (1994) 383-391.
36. 2 antagonist MDL 100,907 on fenfluramine-, MDMA-, or DOI-induced disruption of auditory or visual prepulse inhibition in rats, Soc. Neurosci. Abstr., 19 (1993) 1625.
37. Peters, S.L. and Joseph, M.H., Haloperidol potentiation of latent inhibition in rats: evidence for a critical role at conditioning rather than pre-exposure, Behav. Pharmacol., 4 (1993) 183-186.
38. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat, Eur. J. Pharmacol., 273 (1995) 273-279.
39. Schreiber, R., Brocco, M. and Millan, M.J., Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone, Eur. J.. Pharmacol., 264 (1994) 993-102.
40. Shulgin, A.T., Psychotomimetic drugs: structure-activity relationships. In: L.L. Iversen, S.D. Iversen and S.H. Snyder (Eds.), Handbook of Psychopharmacology, Vol. 11, Plenum Press, New York, 1978, pp. 243-333.
41. 2C receptors, Behav. Pharmacol. 6 (1995) 839-842.
42. Solomon, P.R., Crider, A., Winkelman, J.W., Turi, A., Kamer, R.S. and Kaplan, L.J., Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder, Biol. Psychiatry. 16 (1981) 519-537.
43. Solomon, P.R., Nichols, G.L., Kiernan, J.M., Kamor, R.S. and Kaplan, L.J., Differential effects of lesions in medial and dorsal raphe of the rat: latent inhibition and septohippocampal serotonin levels, J. Comp. Physiol. Psychol., 94 (1980) 145-154.
44. Solomon, P.R., Kiney, C.A. and Scott, D.R., Disruption of latent inhibition following systemic administration of parachlorophenylalanine (PCPA), Physiol. Behav., 20 (1978) 265-271.
45. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies, J. Pharmacol. Exp. Ther., 266 (1993) 684-691.
46. Swerdlow, N.R., Geyer, M.A., Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia, Pharmacol, Biochem. Behav., 44 (1993) 741-744.
47. Swerdlow, N.R., Braff, D.L., Hartston, H., Perry, W. and Geyer, M.A., Latent inhibition in schizophrenia, Schizophr. Res. 20 (1996) 91-103.
48. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens, Psychopharmacology, 94 (1988) 213-216.
49. Warburton, E.C., Joseph, M.H., Feldon, J., Weiner, I. and Gray, J.A., Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron, Psychopharmacology, 114 (1994) 657-664.
50. Weiner, I. and Feldon, J., Facilitation of latent inhibition by haloperidol in rats, Psychopharmacology, 91 (1987) 248-253.
51. Weiner, I., Kidron, R., Tarrasch, R., Amt, J. and Feldon, J., The effects of the new antpsychotic, sertindole, on latent inhibition in rats, Behav. Psychopharmacol., 5 (1994) 119-124.
52. Weiner, I., Lubow, R.E., and Feldon, J., Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol. Biochem. Behav., 30 (1988) 871-878.
53. Weiner, I., Lubow, R.E., and Feldon, J., Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats, Psychopharmacology, 83 (1984) 194-199.
54. Weiner, I., Shadach, E., Tarrasch, R., Kidron, R. and Feldon, J., The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine, Biol. Psychiat., 40 (1996) 834-843.
55. Wettstein, J.G., Host, M. and Hitchcock, J.M., Effects of antipsychotic drugs and other CNS-active agents on the behavioral actions of the hallucinogen DOI (1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane), Soc. Neurosci. Abstr., 22 (1996) 481.
56. 2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex, Br. J. Pharmacol., 99 (1990) 221-222.